NYSE:PFE

Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting

Retrieved on: 
Monday, April 29, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, PFS, Brentuximab vedotin, Triple-negative breast cancer, Lung cancer, MBC, ASCO, Lymphoma, PFE, Metastasis, ALK, Breast cancer, Learning, CRS, Food, Colorectal cancer, Abstract, RRMM, Rituximab, ADC, HR, CDK4, De novo, Spacecraft, DLBCL, Tucatinib, Anaplastic lymphoma kinase, Safety, Crizotinib, Pembrolizumab, Survival, EZH2, Pros, Inc., Neoplasm, Progression-free survival, Recurrence, PAL, Biologics license application, HRR, Hodgkin lymphoma, Patient, Society, Cyclin-dependent kinase 4, Cytokine release syndrome, Annual general meeting, APLS, PBC, Lenalidomide, B-cell lymphoma, Pharmaceutical industry

Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago.
  • “We are excited to participate in our first ASCO Annual Meeting following the creation of Pfizer’s new Oncology organization, where we will highlight our efforts to accelerate breakthrough medicines that help people with cancer live better and longer lives,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.
  • An oral presentation on extended duration of response from the Phase 3 MOUNTAINEER trial adds to the positive profile of TUKYSA in colorectal cancer.
  • Those interested in learning more can visit www.Pfizer.com/apls to access the summaries starting Friday, May 24.

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Retrieved on: 
Monday, April 29, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, PFS, Congress, Pfizer, Peripheral neuropathy, Priority review, Risk, Woman, Food, Progression-free survival, Nausea, Survival, Death, Pneumonitis, Hazard, ESMO, Gynecologic Oncology (journal), OS, Disease, ADC, Patient, PFE, Bleeding, Fatigue, Toxicity, Diagnosis, Constipation, Clinical trial, Mount Sinai Medical Center, Cervical cancer, Nosebleed, Pharmaceutical industry

This FDA action converts the September 2021 accelerated approval of TIVDAK to a full approval.

Key Points: 
  • This FDA action converts the September 2021 accelerated approval of TIVDAK to a full approval.
  • TIVDAK is the first antibody-drug conjugate (ADC) with demonstrated overall survival data to be granted full FDA approval in this patient population.
  • The approval is based on results from the global, randomized, Phase 3 innovaTV 301 clinical trial ( NCT04697628 ), in which TIVDAK met its primary endpoint of overall survival (OS) in patients with previously treated recurrent or metastatic cervical cancer compared to chemotherapy.
  • “Treatment options for patients with advanced or recurrent cervical cancer are limited.

FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer

Retrieved on: 
Monday, April 29, 2024
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, PFS, Congress, Pfizer, Peripheral neuropathy, Priority review, Risk, Woman, Food, Progression-free survival, Nausea, Survival, Death, Pneumonitis, ESMO, Gynecologic Oncology (journal), OS, Disease, Patient, PFE, Bleeding, Fatigue, Toxicity, Constipation, Diagnosis, Inc., Clinical trial, Mount Sinai Medical Center, Cervical cancer, Nosebleed, Pharmaceutical industry

"Recurrent or metastatic cervical cancer is a particularly devastating and mostly incurable disease, and patients are in need of survival-extending treatment options,” said Chris Boshoff, M.D., Ph.D., Chief Oncology Officer, Executive Vice President at Pfizer.

Key Points: 
  • "Recurrent or metastatic cervical cancer is a particularly devastating and mostly incurable disease, and patients are in need of survival-extending treatment options,” said Chris Boshoff, M.D., Ph.D., Chief Oncology Officer, Executive Vice President at Pfizer.
  • Secondary endpoints of progression-free survival (PFS) and confirmed objective response rate (ORR) were also met.
  • Median OS for patients treated with TIVDAK was 11.5 months [95% CI: 9.8-14.9] versus chemotherapy 9.5 months [95% CI: 7.9-10.7].
  • “Treatment options for patients with advanced or recurrent cervical cancer are limited.

U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B

Retrieved on: 
Friday, April 26, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, World government, FIX, Risk, Food, Love, Duchenne, Coalition, Biologics license application, Bleeding, Disease, Patient, PFE, EMA, Medicine, Inc., Standard of care, Duchenne muscular dystrophy, Haemophilia B, European Medicines Agency, Pharmaceutical industry

“For people living with hemophilia, disease management can interfere with many aspects of their lives.

Key Points: 
  • “For people living with hemophilia, disease management can interfere with many aspects of their lives.
  • A one-time infusion of BEQVEZ may allow eligible patients more time for the things they love,” said Kim Phelan, Chief Operating Officer, The Coalition for Hemophilia B.
  • “We are excited to have BEQVEZ as a promising treatment option for eligible people living with hemophilia B.
  • A Biologics License Application and European Marketing Authorization Application for marstacimab are currently under review with the FDA and EMA, respectively.

Pfizer Declares Second-Quarter 2024 Dividend

Retrieved on: 
Wednesday, April 24, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Inc., Pfizer, PFE, Common stock

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 second-quarter 2024 dividend on the company’s common stock, payable June 14, 2024, to holders of the Common Stock of record at the close of business on May 10, 2024.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 second-quarter 2024 dividend on the company’s common stock, payable June 14, 2024, to holders of the Common Stock of record at the close of business on May 10, 2024.
  • The second-quarter 2024 cash dividend will be the 342nd consecutive quarterly dividend paid by Pfizer.

European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options

Retrieved on: 
Monday, April 22, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Mortality, Urinary tract infection, Pyelonephritis, WHO, News, World Health Organization, Safety, Infection, European Commission, Bacteria, Inc., AMR, Aztreonam, HAP, Fungal infection, VAP, Hospital-acquired pneumonia, Gram-negative bacteria, Patient, PFE, Ventilator-associated pneumonia, Parasitism, Multiple drug resistance, Virus, Civil service commission, Fungus, Antimicrobial resistance, Head, Disease, Gram, Vaccine

(NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.

Key Points: 
  • (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.
  • It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
  • “For healthcare teams treating patients with serious Gram-negative bacterial infections, the prospect of running out of effective treatment options is a daunting but very real threat,” said Yehuda Carmeli, Head, National Institute for Antibiotic Resistance and Infection Control, Tel Aviv Medical Center, Israel, and an investigator in the REVISIT study.
  • Marketing authorization applications for EMBLAVEO are planned for submission in other countries.

Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25

Retrieved on: 
Thursday, April 11, 2024
Biotechnology, General Health, Pharmaceutical, Health, Inc., Conduct, Pfizer, Annual general meeting, PFE, EDT, Webcast

Guests may participate in a listen-only mode. No control number is required. A replay of the webcast will be available for up to one year at: https://investors.pfizer.com/Investors/Events--Presentations.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2024 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 25, 2024.
  • Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who attend the virtual-only Annual Meeting will be afforded comparable rights and opportunities to participate as they would at an in-person meeting.
  • Beginning today, shareholders can find additional information on accessing and registering for the virtual meeting at https://meetnow.global/PFE2024 .
  • Shareholders also may submit questions in advance of the meeting by following the instructions provided on the “Rules of Conduct and Meeting Procedures” available on the virtual meeting platform.

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease

Retrieved on: 
Tuesday, April 9, 2024
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Development, Risk, Diabetes, Ageing, Chronic obstructive pulmonary disease, Head, RSV, Senior, Asthma, Safety, Vaccine, Person

Adults with certain underlying chronic conditions are at increased risk of developing, and being hospitalized for, RSV-associated LRTD1,2.

Key Points: 
  • Adults with certain underlying chronic conditions are at increased risk of developing, and being hospitalized for, RSV-associated LRTD1,2.
  • However, no RSV vaccines have been approved for use in adults 18 to 59 years of age.
  • The MONeT study was initiated to address this significant unmet need by investigating the immunogenicity and safety of ABRYSVO in adults aged 18 to 59 at increased risk for RSV disease, such as those with asthma, diabetes, and chronic obstructive pulmonary disease.
  • “These encouraging results provide evidence that ABRYSVO can help protect adults with increased risk against RSV-associated illness,” said Annaliesa Anderson, Ph.D., Senior Vice President and Head, Vaccine Research and Development, Pfizer.

ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager

Retrieved on: 
Monday, April 8, 2024
Health, Kerry Group, Growth, State university system, PFE, American Chemistry Council, DOW, Engineering, Buffalo Niagara, Michigan State University, Safety, Chemical engineering, Project Management Professional, Food, ACC, Corporation, Pharmacia

HOUSTON, April 8, 2024 /PRNewswire/ -- ALTIVIA today announced that it has named Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager.

Key Points: 
  • HOUSTON, April 8, 2024 /PRNewswire/ -- ALTIVIA today announced that it has named Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager.
  • Mr. Barnum will oversee the process management, quality, and operations of ALTIVIA's Specialty and Oxide Chemicals' units.
  • Mr. Hale will lead the development and management of ALTIVIA's Corporate Engineering Department.
  • "We look forward to welcoming both Scott and Dean as ALTIVIA furthers its investment in growth, sustainability, and world-class operating performance," said Michael Jusbasche, ALTIVIA's Chief Executive Officer.